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In Africa,most plasmodium infections during pregnancy remain asymptomatic, yet are
associated with maternal anemia and low birthweight.WHO recommends intermittentpre-
ventive therapy in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP). However, sulfa-
doxine-pyrimethamine (SP) efficacy is threatened by high-level parasite resistance.We
conducted a trial to evaluate the efficacy and safety of scheduled intermittentscreening with
malaria rapid diagnostic tests (RDTs) and treatment of RDT-positive women with dihydroar-
temisinin-piperaquine (DP) as an alternative strategy to IPTp-SP.
Methodsand Findings
This was an open-label, two-arm individually randomized superiority trial among HIV-sero-
negative women at three sites in Malawi with high SP resistance. The intervention consisted
of three or four scheduled visits in the second and third trimester, 4 to 6 wk apart.Women in
the IPTp-SP arm received SP at each visit. Women in the intermittentscreening and
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treatment in pregnancy with DP (ISTp-DP) armwere screened for malaria at every visit and
treatedwith DP if RDT-positive. The primaryoutcomes were adverse live birth outcome
(composite of small for gestational age, low birthweight [<2,500 g], or pretermbirth [<37
wk]) in paucigravidae (first or second pregnancy) and maternal or placental plasmodium
infection at delivery in multigravidae (third pregnancy or higher). Analysis was by intention
to treat.
Between 21 July 2011 and 18 March 2013, 1,873 women were recruited (1,155 pauci-
gravidae and 718multigravidae). The prevalence of adverse live birth outcomewas similar
in the ISTp-DP (29.9%) and IPTp-SP (28.8%) arms (risk difference = 1.08% [95%CI
−3.25% to 5.41%]; all women: relative risk [RR] = 1.04 [95%CI 0.90–1.20],p = 0.625; pauci-
gravidae: RR = 1.10 [95%CI 0.92–1.31],p = 0.282; multigravidae: RR = 0.92 [95%CI 0.71–
1.20], p = 0.543). The prevalence of malaria at delivery was higher in the ISTp-DP arm
(48.7% versus 40.8%; risk difference = 7.85%, [95%CI 3.07%–12.63%]; all women: RR =
1.19 [95%CI 1.07–1.33],p = 0.007; paucigravidae: RR = 1.16 [95%CI 1.04–1.31],p =
0.011; multigravidae: RR = 1.29 [95%CI 1.02–1.63],p = 0.037). Fetal loss was more com-
mon with ISTp-DP (2.6% versus 1.3%; RR = 2.06 [95%CI 1.01–4.21],p = 0.046) and high-
est among non-DP-recipients (3.1%) in the ISTp-DP arm. Limitations included the open-
label design.
Conclusions
Scheduled screening for malaria parasites with the current generation of RDTs three to four
times during pregnancy as part of focused antenatal care was not superior to IPTp-SP in
this area with high malaria transmission and high SP resistance and was associated with
higher fetal loss and moremalaria at delivery.
Trial Registration
Pan AfricanClinical Trials Registry PACTR201103000280319; ISRCTNRegistry
ISRCTN69800930
Author Summary
WhyWas This Study Done?
• Malaria infection during the course of pregnancy can have devastating consequences on
the mother and unborn child.
• Intermittent preventive treatment in pregnancy (IPTp) with the antimalarial sulfadox-
ine-pyrimethamine (SP) is one of the main interventions to protect pregnant women
during pregnancy in malaria endemic areas in sub-Saharan Africa.
• The effectiveness of SP, however, is threatened by increasing resistance of the malaria
parasite to this drug in east and southern Africa.
• We conducted this study to evaluate if an alternative strategy consisting of screening
pregnant women for malaria with rapid diagnostic tests at regular intervals during preg-
nancy and then treating the test-positive women with dihydroartemisinin-piperaquine
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(DP) would reduce the risk of malaria infection and the adverse consequences to the
mother and newborn.This strategy is called intermittent screening and treatment in
pregnancy (ISTp).
What Did the Researchers Do and Find?
• Our team conducted a two-arm, open-label trial to compare the effect of the new ISTp
with DP (ISTp-DP) strategy against the existing IPTp with SP (IPTp-SP) strategy (the
control arm) in 1,873 pregnant women in southernMalawi, where almost all of the
malaria parasites were highly resistant to SP.
• We found that the rate of malaria infectionwas high in both groups and that the new
ISTp-DP strategy was not any better than the existing IPTp-SP strategy in terms of
reducing malaria infection or improving pregnancy outcomes; in fact, women in the
ISTp-DP arm had more malaria than women in the IPTp-SP arm.
What Do These FindingsMean?
• ISTp-DP with the current generation of rapid diagnostic tests is not a viable alternative
strategy to replace IPTp-SP in malaria endemic areas in sub-Saharan Africa, despite the
high levels of resistance to SP.
• IPTp with SP should still be used as one of the interventions against malaria in preg-
nancy in sub-Saharan Africa.
• Further studies to explore alternative drugs that can replace SP for IPTp will be required
in these areas of high SP resistance.
Introduction
Malaria during pregnancy is a major preventable cause of poor birth outcomes in sub-Saharan
Africa [1]. In sub-Saharan Africa, the World Health Organization (WHO) currently recom-
mends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimeth-
amine (SP) (IPTp-SP) for HIV-seronegative women. The effectiveness of IPTp-SP to clear
peripheral parasitemia decreases in areas where parasites are resistant to SP; this resistance
results from a series of mutations in the parasite genes that encode the targets of pyrimeth-
amine (dhfr) and sulfadoxine (dhps). For example, in settings where>90% of parasites harbor
high-level SP resistance encoded by five mutations in dhfr and dhps, up to 40% of asymptom-
atic parasitemic women who receive SP for IPTp are parasitemic again by day 42, reflecting the
failure of SP to clear existing plasmodium infections and prevent new infections [2]. Neverthe-
less, even in these high resistance settings, SP retains some beneficial effect on birthweight
[2,3]. However, an additional mutation at codon 581 in dhps is emerging in parasites in East
Africa that renders IPTp-SP unable to inhibit parasite growth and may significantly compro-
mise IPTp-SP when present [4–6]. Consequently, alternative approaches are required to pre-
vent malaria during pregnancy.
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Most of the proposed alternative drugs to replace SP are too poorly tolerated for IPTp use,
including amodiaquine alone or combined with SP [7], mefloquinemonotherapy [8,9], and the
fixed-dose combination of chloroquine-azithromycin [10]. A proposed alternative strategy to
IPTp consists of scheduled antenatal testing with rapid diagnostic tests (RDTs) and the treat-
ment of RDT-positive women with artemisinin-based combination therapy (ACT), referred to
as intermittent screening and treatment in pregnancy (ISTp) [11]. In West African settings,
where parasite resistance to SP is low, ISTp with artemether-lumefantrine (AL) (ISTp-AL) was
not inferior to IPTp-SP in reducing low birthweight and was well-accepted by providers and
patients [12–14]. Nevertheless, in these studies, women in the ISTp-AL arm had lower mean
birthweights and more clinical malaria during pregnancy.
We hypothesized that, owing to widespread parasite SP resistance, ISTp with the ACT dihy-
droartemisinin-piperaquine (DP) would be superior to IPTp-SP for the prevention of the
adverse sequelae of malaria in pregnancy. However, a recent trial in an area with high levels of
malaria transmission and parasite resistance to SP in western Kenya showed that ISTp with DP
(ISTp-DP) was not superior to IPTp-SP and was associated with increased incidence of clinical
malaria and malaria infection [15]. These findings need to be confirmed urgently in other areas
that have high levels of parasite resistance to SP. Here we report the results of a similar trial
comparing IPTp-SP against ISTp-DP in Malawi.
Methods
Ethics Statement
Ethical approval was obtained from the Liverpool School of Tropical Medicine (LSTM) and
the Malawian National Health Science Research Committee.Written informed consent was
obtained from all participants prior to randomization.
Study Design and Participants
This was a three-site, open-label, two-arm individually randomized superiority trial using a
stratified design with one strata for primi- and secundigravidae (paucigravidae) and one for
multigravidae (third pregnancy or higher). The study was conducted at the Mpemba and Mad-
ziabango Health Centers and the Chikwawa District Hospital in southernMalawi. The area has
moderate to intense year-round malaria transmission and high levels of SP resistance, as evi-
denced by near fixation of parasites harboringmutations at codons 51, 59, and 108 of dhfr and
437 and 540 of dhps [16,17].
Women of all gravidae attending their first antenatal visit were eligible if they were HIV-
seronegative, were resident in the study catchment area and willing to deliver at the study clin-
ics/hospital, had a hemoglobin> 70 g/l, had a pregnancy between 16 and 28 wk gestation, and
had not yet received IPTp-SP. Exclusion criteria includedmultiple gestation and other high-
risk pregnancies according to national guidelines, previous enrollment in the same study, and
history of allergy to any of the study drugs.
Randomization and Masking
Randomization sequences were computer-generated by the study statistician at LSTM, one for
each gravidity strata and study site, using variable block randomization and an allocation ratio
of 1:1. In each clinic, eligible women were allocated to the IPTp-SP or ISTp-DP arm by the
coordinating study staff in order of their study identification number by drawing sequentially
numbered opaque envelopes containing the allocation arm from a box corresponding to each
gravidity stratum. Following allocation, women and care providers were aware of the arm
IST with DP vs IPT with SP for Malaria in Pregnancy in Malawi
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allocation. All laboratory staff were blinded to the treatment assignment. The study statistician
remained blinded until after database lock and approval of the statistical analysis plan by the
data and safety monitoring board.
Procedures
At enrollment, demographic, socioeconomic, and educational information was collected, a
medical and obstetric history taken, and the gestational age ascertained by ultrasound. A 5-ml
venous blood sample was taken for malaria microscopy, PCR, immunology, and testing for
syphilis, HIV serostatus, and hemoglobin concentration (Hemocue). All women received a
long-lasting insecticide-treatednet.
Participants were randomized to receive either IPTp-SP or ISTp-DP, at enrollment and all
subsequent scheduled antenatal visits. The IPTp-SP arm received three tablets of SP (500 mg/
25 mg sulfadoxine/pyrimethamine tablets). If they had fever or history of fever, they were
tested for malaria by RDT. RDT-positive women were treated with AL and then received their
first course of SP during the first scheduled follow-up visit. Women in the ISTp-DP arm were
screened for malaria using the histidine-rich protein 2 (HRP2)/plasmodium lactate dehydroge-
nase (pLDH) combination RDT (First ResponseMalaria pLDH/HRP2 ComboTest, Premier
Medical Corporation). All RDT-positive women in the ISTp-DP arm received a standard 3-d
course of DP (Eurartesim, Sigma Tau; 40 mg/320 mg dihydroartemisinin/piperaquine tablets)
at a dose of 2.5, 3, 3.5, and 4 tablets for women weighing<50, 50–59, 60–69, and70 kg,
respectively. All SP and DP doses were provided with a slice of dry bread as directly observed
therapy. All doses in both arms were supervised. In case of vomiting within 30–60 min, the full
dose was repeated. If the repeat dose was vomited, the women received AL. Sigma Tau pro-
vided the Eurartesim free of charge.
The follow-up schedule consisted of three or four scheduled antenatal visits every 4 to 6 wk:
four if enrolled at 16–24 wk gestation or three if enrolled at 25 wk gestation. At each such
visit, a clinical and obstetric examination was conducted, and a blood sample taken for RDT
(ISTp-DP arm), malaria microscopy, and PCR. Hemoglobin was assessed during the last
scheduled visit. Women were encouraged to make unscheduled visits if they felt ill or were con-
cerned about their pregnancy. In the IPTp-SP arm, women with uncomplicated clinical malaria
(fever/history of fever and RDT-positive) during or in between scheduled visits received AL.
Women with uncomplicated malaria in the ISTp-DP arm receivedDP, or AL if they had
receivedDP within the previous 4 wk.
At delivery, a maternal venous sample was taken for the samemalariametrics, and a placental
and cord-blood sample for histology, RDT, microscopy, and PCR. Childrenwere weighed and the
gestational age assessed using themodifiedBallard score [18]. The presence of congenital abnor-
malities and jaundice was assessed at delivery, at day 7, and at the final visit at 6–8 wk, coinciding
with their childhoodvaccination visit. In between scheduled visits, infants were followed passively.
RDT results were used to determine care. RDT positivity was defined as either pLDH or
HRP2 antigen positivity. See S1 Text for details of microscopy and real-time PCR used for
detection and identification of parasites, as well as baseline parasite genotyping.
Outcomes
The primary outcome among paucigravidae was “adverse live birth outcome,” defined as the
composite of having a singleton baby born small for gestational age (SGA) [19] or with low
birthweight (<2,500 g), or preterm (<37 wk) (S1 Text). The primary outcome among multi-
gravidae was a composite of any evidence for plasmodium infection at delivery detected in
peripheral maternal blood (microscopy, RDT, or PCR) or placenta (incision smear, impression
IST with DP vs IPT with SP for Malaria in Pregnancy in Malawi
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smear, PCR, or active or past infection detected by histology) (S1 Text). The rationale for using
a different primary outcome for multigravidae was based on systematic reviews showing that
preventing plasmodium infection by IPTp-SP or long-lasting insecticide-treatednets is associ-
ated with improved birth outcomes primarily among women in their first and second pregnan-
cies [20,21]. Plasmodium infection status at delivery was used as the primary outcome in
multigravidae because plasmodium infection is associated with an increased risk of malaria
[22–25] and anemia [26–28] in infancy, particularly in those born to multigravidae [24].
Key secondary efficacy outcomes included the individual components of the composite pri-
mary outcomes, fetal loss (spontaneous abortion at <28 wk gestation, stillbirth), any adverse
birth outcome (adverse live birth outcome or fetal loss), maternal hemoglobin concentrations
and anemia, clinical malaria (documented fever/history of fever plus positive malaria RDT),
plasmodium infection,mean birthweight, mean gestational age at delivery, congenital plasmo-
dium infection (cord blood positive at birth by microscopy, RDT, or PCR, or clinical malaria
within 7 d of birth with parasitological confirmed diagnosis by microscopy or RDT), neonatal
and infant (by 6–8 wk) clinical malaria, all-cause severe anemia and all-cause illness detected at
scheduled or unscheduled postnatal visits, and perinatal and infant mortality by 6–8 wk.
The primary safety outcomes includedmaternal death, severe cutaneous skin reaction in
the mothers within 30 d of drug intake, other serious adverse events (SAEs) in the mother or
infant, congenital malformations, and neonatal jaundice.
Statistical Analysis
See S1 Text for details about sample size calculations. Log binomial regression was used for
binary endpoints to obtain relative risk (RR) values and corresponding 95% confidence inter-
vals. The identity-link functionwas used to obtain risk differences. Linear regression was used
for continuous variables, and results expressed as mean difference (95% CI). The unadjusted
analysis, stratified by gravidity (pauci- and multigravidae), was considered the primary analy-
sis. Secondary, covariate-adjusted analyses for the primary endpoints were conducted using
seven prespecified covariates (in addition to gravidity and site) and simple imputation for miss-
ing covariates (<1%). These same covariates were included in subgroup analyses. Poisson
regression with time of follow-up as an offset was used for count variables to obtain incidence
rate ratios (95% CIs). A two-sided p-value< 0.05 was used to define statistical significance.
The intention to treat (ITT) analytical population was defined as all eligible women who were
randomized and contributed to the outcome. The per protocol population included women
who attended every scheduled visit, who took all the daily study doses on each occasion, and
who contributed to the endpoint. For the safety analysis, women in the ISTp-DP arm were con-
sidered overall and split by recipients and non-recipients of DP (i.e., those who were RDT-neg-
ative throughout). All analyses were prespecified, unless otherwise indicated, in a statistical
analysis plan (see S2 Text) approved by the data and safety monitoring board. Analysis was
done in SAS version 9.3 and Stata version 14.
Results
Baseline and Patient Disposition
Between 21 July 2011 and 18 March 2013, 3,214 women were screened for inclusion; 1,873
women were randomized (paucigravidae, n = 1,155; multigravidae, n = 718). Recruitment was
stopped when the full sample size for paucigravidae had been reached (S1 Text). Of the ran-
domized women, 1,743 (93.1%) were seen at delivery (Fig 1). Overall, 6,504 of 6,942 (93.7%)
scheduled antenatal follow-up visits were attended (S1 Table), and 1,742 women (94.5%)
attended all scheduled visits. Ultimately, 1,676 (89.5%) contributed to the primary endpoint,
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with proportions of participants equally distributed between the study arms (ISTp-DP arm,
89.3%; IPTp-SP arm, 89.6%) (S2 Table). The baseline characteristics were well balanced between
the study arms, within each gravidity strata, and overall (Table 1). At baseline, about half of the
women were infectedwith malaria parasites, and this proportion was slightly lower (not signifi-
cant) in those not contributing to the primary analyses (S3 Table). Overall, 99.5% and 2.7% of
the parasites harbored the dhps K540E and A581Gmutation, respectively (S4 Table). In both
arms, the median (interquartile range) follow-up time was 4.0 (3.2–4.7)mo, and the median
(range) number of scheduled visits was 4 (1–4) (S1 Table). In the ISTp-DP arm, 48.8%, 38.0%,
12.4%, and 0.9% received 0, 1, 2, and 3 courses of DP, respectively (S1 Table). Overall, 3,048 and
604 courses of SP and DP were administered in the respective study arms, and in the IPTp-SP
arm, 251 courses of AL were administered for clinical malaria (S1 Table).
PrimaryOutcome
Among paucigravidae, the prevalence of adverse live birth outcome was similar in the ISTp-DP
(33.7%) and IPTp-SP (30.6%) arms (RR = 1.10 [95% CI 0.92–1.31], p = 0.282; Fig 2). The prev-
alence was also similar between arms among multigravidae.
Fig 1. Flow chart. aOne woman randomized to IPTp-SPwas erroneously recorded as being in the ISTp-DParmon her antenatal care card and as
a result received ISTp-DP. She was included in the ITT population under the IPTp-SP arm. bScreening failures were not followed to delivery and
were excluded from themodified ITT population. cWomen lost to follow-up prior to delivery and womenwho withdrew consent were included in the
ITT population and contributed to the antenatal follow-up analyses (e.g., incidence of malaria). IPTp-SP, intermittentpreventive therapy in
pregnancywith sulfadoxine-pyrimethamine; ISTp-DP, intermittentscreening and treatment in pregnancywith dihydroartemisinin-piperaquine; ITT,
intention to treat; SGA/LBW/PT, small for gestational age or low birthweight or preterm.
doi:10.1371/journal.pmed.1002124.g001
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Table 1. Baseline characteristics (intentionto treat population).
Characteristic Paucigravidae Multigravidae All Gravidae (Pooled)
ISTp-DP (n = 571) IPTp-SP (n = 569) ISTp-DP (n = 352) IPTp-SP (n = 352) ISTp-DP (n = 923) IPTp-SP (n = 921)
Maternal characteristics
Study site
Madziabango 21.9% (125/571) 22.1% (126/569) 31.3% (110/352) 30.4% (107/352) 25.5% (235/923) 25.3% (233/921)
Mpemba 51.5% (294/571) 51.5% (293/569) 54.3% (191/352) 55.4% (195/352) 52.6% (485/923) 53.0% (488/921)
Chikwawa 26.6% (152/571) 26.4% (150/569) 14.5% (51/352) 14.2% (50/352) 22.0% (203/923) 21.7% (200/921)
Maternal age (years) 19.5 (2.7) 19.6 (2.8) 27.3 (4.3) 27.5 (4.2) 22.5 (5.1) 22.6 (5.1)
Marital status
Single 8.1% (46/570) 8.8% (50/569) 2.0% (7/351) 0.3% (1/352) 5.8% (53/921) 5.5% (51/921)
Married 91.9% (524/570) 91.2% (519/569) 97.7% (343/351) 99.1.% (349/352) 94.1% (867/921) 94.2% (868/921)
Widowed/separated/
divorced
0.0% (0/570) 0.0% (0/569) 0.3% (1/351) 0.6% (2/352) 0.1% (1/921) 0.2% (2/921)
Used a bednet last night 18.2% (104/571) 17.0% (97/569) 18.2% (64/351) 24.1% (85/352) 18.2% (168/922) 19.8% (182/921)
Schooling (years
completed)
6.7 (3.4) 6.7 (3.3) 4.4 (3.4) 4.4 (3.9) 5.8 (3.6) 5.9 (3.7)
SES index score (terciles)
Low 34.7% (198/570) 33.3% (189/567) 33.3% (117/351) 31.5% (111/352) 34.2% (315/921) 32.6% (300/919)
Medium 31.2% (178/570) 32.1% (182/567) 37.0% (130/351) 36.1% (127/352) 33.4% (308/921) 33.6% (309/919)
High 34.0% (194/570) 34.6% (196/567) 29.6% (104/351) 32.4% (114/352) 32.4% (298/921) 33.7% (310/919)
Rainfall in the 3 mo before
enrollment (average/
month, in millimeters)
22.8 (3.0–117.5) 22.8 (3.0–117.5) 23.8 (3.3–117.5) 24.7 (3.3–117.5) 22.8 (3.3–117.5) 22.8 (3.3–117.5)
Pregnancy number
(gravidity)
First 54.5% (311/571) 55.5% (316/569) NA NA 33.8% (311/921) 34.3% (316/920)
Second 45.5% (260/571) 44.5% (253/569) NA NA 28.2% (260/921) 27.5% (253/920)
Third NA NA 44.0% (154/352) 43.0% (151/351) 16.7% (154/921) 16.4% (151/920)
Fourth or higher NA NA 56.0% (196/352) 57.0% (200/351) 21.3% (196/921) 21.7% (200/920)
Gestational age by
ultrasound (days)
145.1 (23.0) 144.5 (22.4) 149.7 (23.7) 149.1 (23.8) 146.8 (23.3) 146.2 (23.0)
Had a previous stillbirth/
abortion
5.1% (29/571) 4.0% (23/569) 14.2% (50/352) 10.8% (38/352) 8.6% (79/923) 6.6% (61/921)
Maternal weight
(kilograms)
54.1 (6.8) 54.4 (6.9) 56.1 (7.5) 57.0 (8.5) 54.8 (7.2) 55.4 (7.6)
Maternal height
(centimeters)
153.6 (4.8) 154.0 (5.0) 154.2 (5.2) 154.5 (5.0) 153.8 (5.0) 154.2 (5.0)
Laboratory findings
Hemoglobin (g/dl) 10.7 (1.5) 10.7 (1.5) 11.5 (1.3) 11.5 (1.3) 11.0 (1.5) 11.0 (1.4)
Plasmodium infection
RDT 43.8% (250/571) NA 19.4% (68/351) NA 34.5% (318/922) NA
Microscopy 17.7% (100/565) 20.8% (117/562) 11.8% (41/347) 9.4% (33/351) 15.5% (141/912) 16.4% (150/913)
PCR 51.3% (285/556) 51.7% (290/561) 33.1% (115/347) 28.7% (98/342) 44.3% (400/903) 43.0% (388/903)
Microscopy or PCR 52.5% (300/571) 54.9% (312/568) 36.4% (128/352) 31.5% (111/352) 46.4% (428/923) 46.0% (423/920)
Parasite densitya 1,000 (320–7,200) 2,427 (507–9,600) 320 (160–3,200) 907 (213–4,267) 800 (267–5,867) 2,400 (320–8,000)
Data are percent (n/N), mean (standard deviation), or median (interquartile range).
aParasite density per microliter, assessed by microscopy.
IPTp-SP, intermittentpreventive therapy in pregnancywith sulfadoxine-pyrimethamine; ISTp-DP, intermittentscreening and treatment in pregnancy with
dihydroartemisinin-piperaquine; NA, not applicable; RDT, rapid diagnostic test; SES, socioeconomic status.
doi:10.1371/journal.pmed.1002124.t001
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Among multigravidae, the risk of malaria at delivery was higher in the ISTp-DP (34.9%)
than in the IPTp-SP (27.2%) arm (RR = 1.29 [95% CI 1.02–1.63], p = 0.037). This increased
risk was also evident among paucigravidae and all gravidae. In absolute terms, the risk of
malaria was increased in multigravidae by 7.8% (95% CI 0.6%–14.9%) and amongst all gravi-
dae by 7.9% (95% CI 3.1%–12.6%) (Fig 2).
Similar results for both primary outcomes were obtained from prespecified covariate-
adjusted analyses, with and without prespecified imputation for missing covariates (S5 Table),
with per protocol population analysis (S6 Table), and in a sensitivity analysis that restricted
analysis to birthweight obtained within 24 h of delivery (S7 Table). Results were also consistent
across subgroups (S1 and S2 Figs), although the increased risk of malaria at delivery appeared
lowest in primigravidae (S2 Fig).
SecondaryEfficacy Outcomes
Following enrollment, 45.8% of women had1 episode of plasmodium infection prior to
delivery (PCR,microscopy, or RDT), and 11.4% had1 episode of clinical malaria. These pro-
portions were similar in both arms (Fig 3). At delivery, 22.2% of women had peripheral malaria
detected by PCR, RDT, or microscopy. This value was higher in the ISTp-DP arm (RR = 1.34
[95% CI 1.12–1.61], p = 0.002; S3 Fig), particularly for subpatent infections (PCR-positive,
RDT- or microscopy-negative; S3 Fig). The overall prevalence of placental malaria detected by
histology, PCR, RDT, or microscopy was 38.0%, and this value was higher in the ISTp-DP arm
Fig 2. Efficacyof ISTp-DPversus IPTp-SPon the primary outcomes of adverse live birthoutcomeandmaternal or placental plasmodium
infectionat delivery (anymeasure).AdjustedRR values obtained frommultivariate log binomial regressionmodels withmissing values imputed
and adjusting for gravidity, study site, and seven other prespecified covariates: malaria status at enrollment (binary), season during pregnancy
(terciles based on average ranked rainfall during the last 6 mo of pregnancy), maternalheight (terciles), hemoglobin status at enrollment (terciles),
maternal years of schooling (terciles), socioeconomic status (terciles of socioeconomic index calculated using principal component analysis), and
gestational age at first antenatal visit (binarybased onmedian). There were no differences in effect size for paucigravidae versus multigravidae (p-
value for interaction term:p = 0.271 for adverse live birthoutcomeand p = 0.454 for plasmodium infection at delivery). IPTp-SP, intermittent
preventive therapy in pregnancywith sulfadoxine-pyrimethamine; ISTp-DP, intermittent screening and treatment in pregnancywith
dihydroartemisinin-piperaquine; LBW, low birthweight; RR, relative risk; SGA, small for gestational age.
doi:10.1371/journal.pmed.1002124.g002
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Fig 3. Secondarymaternal outcomes: anemia andmalaria.The p-value for the interaction termdepicts the p-value for differences in effect
size between paucigravidae andmultigravidae. *Data given as the number of womenwith an event, the number of events/person-years of
follow-up, and, in parentheses, the incidence rate per 100 person-years. #Maternalplasmodium infection detected by PCR, microscopy, or RDT.
RDT data considered only when womenwere symptomatic (febrile). To allow for comparison between study arms, the routine scheduledRDT
data in the ISTp-DParmwere not included. Hb, hemoglobin; IPTp-SP, intermittentpreventive therapy in pregnancywith sulfadoxine-
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(RR = 1.16 [95% CI 1.03–1.32], p = 0.018; S4 Fig), reflecting differences in acute rather than
chronic or past histological infections (S4 Fig). Congenital malaria was common (12.0%) in
both groups (Fig 4).
At delivery, relative to the IPTp-SP arm, paucigravidae in the ISTp-DP arm had higher
mean hemoglobin concentrations (S8 Table) and a lower prevalence of anemia
(hemoglobin< 110 g/l) (Fig 3). The individual components of the primary endpoint adverse
live birth outcome are provided in Fig 4. Low birthweight was more common in the ISTp-DP
arm (RR = 1.29 [95% CI 0.97–1.71], p = 0.079).
Adherence, Tolerance, Fetal Loss, Mortality, and Other Safety
Outcomes
Overall, DP was well tolerated (S9 Table). There was no difference between arms in the number
of maternal SAEs or deaths (S10 Table). There were no severe cutaneous reactions. Fetal loss
was highest in the ISTp-DP arm (2.6% versus 1.3%; Fig 4). Further stratified analysis within the
ISTp-DP arm showed fetal loss was highest among women who had never receivedDP (i.e.,
who remained RDT-negative throughout) (3.1% versus 2.2% in DP recipients; S10 Table). Peri-
natal and infant (by 6–8 wk) mortality were not statistically different between the arms (perina-
tal mortality: RR = 1.62 [95% CI 0.87–2.99], p = 0.127; infant mortality: RR = 1.42 [95% CI
0.63–3.17], p = 0.398) (Fig 4), but overall, the composite of fetal loss or infant death by the end
of follow-up (6–8 wk) occurredmore often in the ISTp-DP arm (4.0% versus 2.3%, RR = 1.76
[95% CI 1.04–2.98], p = 0.036; Fig 4; S10 Table). One case of neonatal jaundice was detected in
the ISTp-DP arm (mother was a non DP-recipient), and none in the IPTp-SP arm. The fre-
quency of congenital malformations was 1.2% in the ISTp-DP arm (0.9% in infants whose
mother was a DP-recipient) and 1.0% in the IPTp-SP arm (RR = 1.11 [95% CI 0.45–2.71],
p = 0.824).
Discussion
Despite the high levels of parasite resistance to SP, ISTp-DP was not superior to the standard
IPTp-SP regimen in this trial: ISTp-DP was not associated with improvements in the compos-
ite outcome of small for gestational age, low birthweight, and preterm birth (primary outcome
for paucigravidae) and was associated with more malaria at delivery (primary outcome for
multigravidae) and more fetal loss. Although the relative increase in malaria risk was modest,
this affected an additional eight out every 100 pregnancies. These results suggest that ISTp-DP
may not be a suitable alternative strategy to replace IPTp-SP in settings similar to ours and
may even predispose to unfavorable pregnancy outcomes in these settings.
The results may not be representative of areas where>10% of parasites harbor the “sextuple
mutant” haplotype carrying the dhps A581Gmutation [29]; however, our efficacy findings are
similar to those reported recently from areas in western Kenya [15] with similarly high trans-
mission (malaria prevalence detected by PCR at enrollment 33% versus 44% in this study) and
SP resistance (5.8% dhps A581Gmutation), and are also consistent with two previous non-infe-
riority trials conducted inWest Africa, despite marked geographic differences in prevailing SP
resistance, which is low inWest Africa [11,12]. In bothWest African studies, ISTp was non-
inferior to IPTp-SP in the reduction in low birthweight among paucigravidae; mean birth-
weights were higher in the IPTp-SP recipients than in those receiving ISTp-AL (p = 0.04) [12],
pyrimethamine; IRR, incidence rate ratio; ISTp-DP, intermittent screening and treatment in pregnancywith dihydroartemisinin-piperaquine; py,
person-years; RR, relative risk.
doi:10.1371/journal.pmed.1002124.g003
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Fig 4. Secondarynewborn outcomes: birthoutcomes and neonatal follow-up. The P-value for the interaction termdepicts the p-value for
differences in effect size between paucigravidae andmultigravidae. IPTp-SP, intermittentpreventive therapy in pregnancywith sulfadoxine-
pyrimethamine; ISTp-DP, intermittentscreening and treatment in pregnancy with dihydroartemisinin-piperaquine; RR, relative risk.
doi:10.1371/journal.pmed.1002124.g004
IST with DP vs IPT with SP for Malaria in Pregnancy in Malawi
PLOSMedicine | DOI:10.1371/journal.pmed.1002124 September 13, 2016 12 / 19
but there was no significant difference compared to those receiving ISTp with amodiaquine-
artesunate (p = 0.06) [11]. Additionally, the incidence of clinical malaria was higher in the
ISTp-AL arm compared to the IPTp-SP arm. This was not observed in our trial, but the trial in
western Kenya also observedhigher incidence of clinical malaria as well as of plasmodium
infection during pregnancy [15].
BecauseDP has very high anti-parasitic efficacy in Africa [30], the lack of superiority of
ISTp-DP may result either from the ineffectivenessof ISTp as a strategy in highmalaria transmis-
sion areas or from the continued effectiveness of IPTp-SP despite prevalent SP resistance. To this
latter point, in our study area inMalawi, 99.5% of parasites harbor the “quintuple mutant” haplo-
type, but only 2.6%–4% carry the additional dhps A581Gmutation [29]. Therefore, it is likely
that IPTp-SP continued to provide some benefits, as has been observed in settings with similar
parasite populations [2,3]. Another factor likely contributing to continued effectiveness of IPTp-
SP was our use of the frequent dosing regimen [31] now recommended byWHO, whichmay
mitigate the shortening of posttreatment prophylaxis that results from SP resistance [2]. It would
also be of interest to further explore whether SP, which also has broad antimicrobial activity, may
have conferred additional protection from other pathogens [32].
It is unlikely that suboptimal dosing or subtherapeutic levels of DP contributed to the non-
superior performance of ISTp-DP: each dose was supervised, and there is no evidence that
pregnancy alters the pharmacokinetics of DP to a degree that requires dose adjustment [33].
The same DP regimen was shown to be highly effective (PCR-corrected success rate by day 63:
99%) in a concurrent treatment trial conducted by the same team in this area using the same
batch [34].
ISTp-DP may also have been ineffective owing to a failure to detect low-level parasitemias,
although the biological impact of such infections during pregnancy is unclear [35]. RDTs
detected about 45% of the PCR-positive infections in paucigravidae and about 30% in multigra-
vidae, thereby allowing the majority of infections to persist in the placenta. Conceptually, ISTp
is intended to prevent both existing infections from progressing and new infections from
occurring for up to 6 wk after each DP course. Because only the RDT-positive women receive
treatment, many do not benefit from the posttreatment prophylaxis. Furthermore, the infre-
quency of screening (approximately monthly) in a high transmission setting may have allowed
new infections to develop and persist between scheduled visits. These factors combined may
explain the higher prevalence of plasmodium infections at the time of delivery in the ISTp-DP
arm.
The ineffectiveness of ISTp to prevent malaria in high transmission settings may also
explain the higher rate of fetal loss in the ISTp-DP arm (2.6% versus 1.3%), consistent with the
results from previous meta-analyses that showed a 1.5-fold higher risk of fetal loss among
women randomized to control arms in trials of insecticide-treatednets [36]. The excess risk of
fetal loss was not due to an adverse effect of DP, as the risk was highest among women who
had never received DP (3.1% versus 2.2%). An alternative explanation could be that the broad
antimicrobial effect of SP reduced the risk of fetal loss relative to ISTp [32]. Lastly, the effect
could also be a chance finding, as the trial in Kenya did not observe an excess risk of fetal loss
in the ISTp arm [15].
Overall, DP was well tolerated, which is consistent with the results of a recent four-arm
treatment trial comparing the four fixed-doseACTs in the case management of malaria in
pregnancy [34]. This is important as almost all RDT-positive women in our trial were asymp-
tomatic, and tolerance can be a major factor determining adherence.
ISTp is a labor-intensive strategy, but a separate qualitative substudy using in-depth inter-
views and focus group discussions showed it was highly acceptable to both patients and clinic
staff. Although ISTp requires more frequent blood sampling, women appreciated its
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importance and the fact that they could be shown the RDT test results, corroborating findings
from similar acceptability studies in Ghana [14,37]. The venous sampling at the first antenatal
visit was deemedmore convenient by women than repeated finger pricks, as it allowed health
workers to tests for malaria, anemia, syphilis, and HIV testing with a single blood draw.
Limitations of our trial include the open-label design used. Another limitation is that we
were not able to include a third arm with IPTp with DP as there was insufficient safety infor-
mation for repeat courses of DP available at the time this trial was designed. Approximately 9%
of the randomized women did not contribute to the primary outcome of adverse live birth out-
come and 12% did not contribute to the primary outcome of plasmodium infection at delivery.
However, this loss to follow-up was well balanced between the study arms, with little differ-
ences in baseline characteristics between those who contributed to the primary endpoint versus
those who did not; thus, this loss to follow-up is unlikely to have biased the findings. The pro-
portion of multigravidae reporting using a bednet the night prior to enrollment was slightly
lower in the ISTp-DP arm; however, this did not explain the observeddifference in the risk of
plasmodium infection at delivery, as all women received an insecticide-treatednet on enroll-
ment, and bednet use thereafter was near universal in both arms (99% in each arm).
ISTp-DP was not superior to the existing IPTp-SP regimen in this area with high SP resis-
tance in southernMalawi. These results should be equally relevant to other high endemic areas
in east and southern Africa with similar or lower levels of parasite SP resistance. The identifica-
tion of alternative drugs to replace SP remains a pressing research priority for the control of
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